PRNB Principia Biopharma Inc.

51.2
0  0%
Previous Close 51.2
Open
Price To Book 10.99
Market Cap 1,678,674,432
Shares 32,786,610
Volume 0
Short Ratio
Av. Daily Volume 340,394
Stock charts supplied by TradingView

NewsSee all news

  1. Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call Schedule

    NEW YORK, Jan. 27, 2020 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a report explaining its short position in Principia Biopharma Inc. (NASDAQ: PRNB), a biopharmaceutical company whose

  2. Principia Announces Expansion of its BTK Franchise with PRN473 Topical

    Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) --

  3. Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

    Company's lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Principia

  4. Principia Updates PRN1008 Pemphigus Clinical Program

    SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with

  5. Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2021.
Rilzabrutinib PRN1008 - PEGASUS
Pemphigus
Phase 2 data at ASH December 2019 noted 39% of patients achieved primary endpoint. Data to be presented 2H 2020.
PRN1008
Immune thrombocytopenic purpura (ITP)
Phase 2 data due 1Q 2020.
SAR442168 (PRN2246)
Multiple sclerosis
Phase 1 dose escalation data released May 20, 2019. Stable disease in 11/ 36 patients.
PRN1371
Urothelial Carcinoma
Phase 2 Part B data to be presented 1H 2020.
Rilzabrutinib PRN1008
Pemphigus
Phase 2 trial to be initiated 1H 2020.
Rilzabrutinib PRN1008
IgG4-related disease (IgG4-RD)
Phase 1 trial to be initiated 1H 2020 with data due 2020.
PRN473

Latest News

  1. Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call Schedule

    NEW YORK, Jan. 27, 2020 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a report explaining its short position in Principia Biopharma Inc. (NASDAQ: PRNB), a biopharmaceutical company whose

  2. Principia Announces Expansion of its BTK Franchise with PRN473 Topical

    Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) --

  3. Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

    Company's lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Principia

  4. Principia Updates PRN1008 Pemphigus Clinical Program

    SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with

  5. Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced

  6. Principia to Present at the Stifel Healthcare Conference 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  7. Principia Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today

  8. Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced

  9. Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

    Consistent efficacy and safety profile for pemphigus patients observed  Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif.,

  10. Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with

  11. Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with